Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We read with great interest the article by Gerbes et al, 1 which indicated the prospects of immune-based therapies in hepatocellular carcinoma (HCC) and that by Zhu et al, 2 which proposed their new strategy for sensitising HCC to anti-programmed death-ligand 1 (PD-L1) blockade. As they suggest, immunotherapy for HCC has great potential, and combination therapy may further improve survival benefits.
Many patients with HCC have advanced stage disease (aHCC) at the time of diagnosis, and some of them even have progressive disease after first-line therapy. Recently, the clinical benefits of immunotherapy for HCC have emerged. Blocking the PD‐1/PD‐L1 signalling pathway with humanised monoclonal antibodies is effective in alleviating immune escape and enhancing T cell‐mediated antitumour immunity. However, no more than 20% of patients with HCC robustly respond to anti-programmed cell death protein 1 (PD-1)/PD-L1 monotherapy.3 4 The combination of anti-vascular endothelial growth factor (VEGF) agents with PD‐1/PD‐L1 blockade may synergistically reverse the immunosuppressive microenvironment.5 Preclinical and …
Contributors ZF contributed to the study concept and design. ZF and PR acquired, analysed and interpreted the data. ZF performed the statistical analysis and drafted the manuscript. ZF, RP and WW made critical revisions to the manuscript. PR and WW supervised the study.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.